India IPO Pipeline SEBI Regulatory Filings — April 18, 2026

Board approval for Diane Enberg Jurgens (ex-CIO Disney 2020-2023, CTO BHP 2015-2020) as additional independent director effective April 22, 2026 for 3-year term, enhancing tech/sustainability expertise

Re-appointment of Helene Auriol Potier as independent director for second 5-year term from May 26, 2026 to May 25, 2031, welcomed by Lead Director and Chairman for global operations strength

NCLT order dated April 15, 2026 directs meetings for scheme approval with 90.96% secured creditor consent via affidavit, equity meeting set for May 27, 2026

Audited standalone/consolidated financial results for Q4 and FY26 ended March 31, 2026 announced April 18 via BSE (532174), high materiality 8/10 vs other bank filings

Corporate action filing aligns with results release, medium risk level and materiality 7/10 indicating structured disclosure amid earnings season

Investor presentation released under Reg 30 SEBI LODR post-board meeting, providing potential forward-looking insights despite no metrics disclosed

Board meeting outcome on Q4/FY26 results announced April 18 via BSE (532648), low risk supports stability in banking disclosures

Both director nominees independently verified, no SEBI debarments, no relationships with board, boosting governance score

Modified meeting dates approved (secured creditors May 27 10AM, unsecured May 27 11AM), scheme subject to approvals keeps momentum

Board outcome disclosed April 18, clusters with multiple filings signaling comprehensive quarterly update

Compliant SEBI LODR disclosure on board decisions, no negative flags in neutral sentiment

4 clustered filings on same day (results, board, corp action, update) vs Yes Bank's 2, relative outperformance in disclosure volume

NCLT denied dispensation of secured creditors meeting despite 90.96% consent affidavits, clarifying prior April 2 order and requiring full May 27 10AM meeting

Composite scheme for Apollo Hospitals, Healthco, Keimed, Healthtech remains subject to creditor/shareholder approvals and final NCLT sanction post-May meetings

Board meeting and results outcome April 18 with no specific financial metrics, dividends, or actions disclosed, materiality only 1-2/10

Audited Q4/FY26 results announced but no metrics, trends, or forward-looking statements in summary, despite 8/10 materiality

Investor presentation released with all key metrics/forward-looking NOT_DISCLOSED, low materiality 2/10

No leadership changes, dividends, or decisions specified, materiality 1/10 and neutral sentiment

Repeated low materiality filings (1-2/10) with no quantitative enriched data on ratios or operations, potential underperformance vs ICICI

Fees cover all meetings but tribunal modifications to May 26-27 dates could delay scheme vs original timeline

Shareholder approval pending for directors with deep tech expertise (Disney/BHP), potential governance premium and stock catalyst pre-AGM

Equity shareholders meeting May 27 2:30PM offers approval catalyst for composite arrangement unlocking value in Healthco/Keimed entities

90.96% secured creditor support positions May 27 10AM meeting for quick passage, merger alpha in healthcare

High materiality 8/10 Q4/FY26 results enable post-announcement analysis for YoY trends in NIM, loans vs peers like Yes Bank

Helene Auriol Potier re-appointment leverages existing profile/link, sustainability focus aligns with ESG inflows

Reg 30 update April 18 provides entry for detailed financials review, cluster filings signal comprehensive info flow

Tribunal order April 15 advances scheme despite hurdles, relative outperformance vs stalled deals

Medium risk 7/10 filing ties to results, opportunity to spot capital allocation/buybacks in full disclosures

Low risk neutral results/board outcomes position as defensive vs ICICI's higher materiality volatility

ICICI/Yes clustered April 18 releases create peer comparison alpha on undisclosed enriched metrics like ROE/debt trends

6/8 filings from ICICI (4) and Yes Bank (2) on April 18 around Q4/FY26 results/board, no YoY metrics but high volume vs other sectors signals earnings focus [IMPLICATION: Peer benchmarking opportunity]

Infosys positive sentiment on dual independent director appointments (3+5 year terms), no insider sales/pledges noted, contrasts neutral bank filings [IMPLICATION: ESG/governance tailwind]

Apollo's NCLT-directed meetings (May 26-27) with 90.96% consent despite denial, sole filing but materiality 7/10 highlights consolidation [IMPLICATION: M&A unlock for unlisted arms like Healthco]

6/8 filings neutral (incl. all banks), positive only Infosys, no bearish; limited enriched data on margins/ROE hides potential trends [IMPLICATION: Wait for full results before positioning]

No period comparisons (YoY/QoQ), insider activity, or capital allocation across filings, high materiality ICICI outlier at 8/10 [IMPLICATION: Alpha from post-filing analysis]

Apollo meetings May 26-27, Infosys terms May 26, builds calendar post-April bank results [IMPLICATION: Time entries around votes]

Monitor approval for composite scheme, May 27, 2026 at 2:30 PM, potential value unlock

Watch for passage despite 90.96% consent denial, May 27, 2026 at 10:00 AM

Key for Healthco, May 27, 2026 at 11:00 AM, final NCLT sanction post-votes

Track votes for Diane Enberg Jurgens (eff. Apr 22, 2026) and Helene Auriol Potier (May 26, 2026), governance catalyst

Analyze full audited metrics for YoY loan growth, NIM trends vs Yes Bank, post-April 18 release

Review for forward-looking guidance, capital allocation undisclosed in summary, immediate post-April 18

Monitor for any follow-up on undisclosed decisions/dividends from April 18 meetings, low materiality flags

Watch for enriched details on actions tying to results, medium risk evolution post-April 18